NCT00768287已完成2 期
Phase I/II/III Pharmacokinetic and Outcome Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 77
- 试验地点
- 46
- 主要终点
- Degree of Hemorrhage Control by Treatment Regimen
研究概览
简要总结
Primary Objective:
To evaluate the safety (acute effects associated with infusions, and inhibitor development), pharmacokinetics (PK), and efficacy with respect to breakthrough bleeding during prophylaxis and with respect to control of hemorrhaging in both the prophylaxis and on demand groups of IB1001 in subjects with hemophilia B.
Key Secondary Objectives:
To evaluate the ability of IB1001 to provide coverage against bleeding under surgical circumstances; To evaluate the long-term safety and efficacy of IB1001
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Study Part 1 only
入排标准
- 年龄范围
- 5 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must be willing to give written Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent, make the required study visits, and follow instructions while enrolled in the study
- •Severe (factor IX activity ≤2 U/dL) hemophilia B subjects on demand therapy with a minimum of 3 bleeding episodes over the preceding 6 months or 6 bleeding episodes over the preceding 12 months; subjects on prophylaxis with a bleeding pattern as above demonstrated prior to starting prophylaxis
- •Immunocompetent (CD4 count >400/mm3) and not receiving immune modulating or chemotherapeutic agents
- •Previously treated patients with a minimum of 150 exposure days to a factor IX preparation
- •Platelet count at least 150,000/mm3
- •Liver function: alanine transaminase [ALT] and aspartate transaminase [AST] ≤2 times the upper limit of the normal range
- •Total bilirubin ≤1.5 times the upper limit of the normal range
- •Renal function: serum creatinine ≤1.25 times the upper limit of the normal range
- •Willingness to participate in the trial for up to 12-15 months
- •European Union (EU), Israel, and Canada: Age of at least 12 years and body weight of ≥40 kilograms to participate in any PK Study or the Surgical Sub-study [the Surgical Sub-study does not apply to the UK]; age of at least 12 years for the prophylaxis and on demand components of the Treatment Phase and Continuation Study
- •United States (US): Age of at least 12 years and body weight of ≥40 kilograms to participate in any PK Study or the Surgical Sub-study; age of at least 5 years for the prophylaxis and on demand components of the Treatment Phase and Continuation Study
- •Hemoglobin ≥7 g/dL at the time of the blood draw
排除标准
- •History of factor IX inhibitor ≥0.6 Bethesda units (BU)
- •Existence of another coagulation disorder
- •Evidence of thrombotic disease, fibrinolysis, or disseminated intravascular coagulation (DIC)
- •Use of an investigational drug within 30 days prior to study entry
- •On medications that could impact hemostasis, such as aspirin
- •History of poor compliance, a serious medical or social condition, or any other circumstance that, in the opinion of the investigator, would interfere with participation or compliance with the study protocol
- •History of adverse reaction to either plasma-derived factor IX or recombinant factor IX that interfered with the subject's ability to treat bleeding episodes with a factor IX product
结局指标
主要结局
Degree of Hemorrhage Control by Treatment Regimen
时间窗: Prophylaxis Group Duration of Treatment: 17.9 ± 9.6 months; On Demand Group Duration of Treatment: 15.9 ± 11.5 months
Subject rating of bleed control within 6 hours of the time bleeding has stopped: 1. Excellent: a dramatic response with abrupt pain relief and clear reduction in joint or hemorrhage site size; 2. Good: pain relief or reduction in hemorrhage site size that may have required an additional infusion for resolution; 3. Fair: probable or slight beneficial response usually requiring one or more additional infusions for resolution; 4. Poor: no improvement or condition worsens.
次要结局
- Concentration (Max)(Pre-infusion to 72 hours following infusion)
- Incremental Recovery(Pre-infusion to 72 hours following infusion)
- Volume of Distribution (Steady State)(Pre-infusion to 72 hours following infusion)
- Area Under the Curve (0-inf)(Pre-infusion to 72 hours following infusion)
- Area Under the Curve (0-72 hr)(Pre-infusion to 72 hours following infusion)
- Terminal Half-life(Pre-infusion to 72 hours following infusion)
- Mean Residence Time(Pre-infusion to 72 hours following infusion)
- Clearance(Pre-infusion to 72 hours following infusion)
- Annualized Bleed Rate(Prophylaxis Group Duration of Treatment: 17.9 ± 9.6 months; On Demand Group Duration of Treatment: 15.9 ± 11.5 months)
研究者
研究点 (46)
Loading locations...
相似试验
终止
1 期
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.HistiocytosisHairy Cell LeukemiaColorectal CancerMelanomaNon-small Cell Lung CancerCholangiocarcinomaThyroid CancerNCT02012231Fore Biotherapeutics5
招募中
1 期
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT04494503Ascentage Pharma Group Inc.123
已完成
1 期
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney DiseasePolycystic Kidney, Autosomal DominantNCT01559363Kadmon, a Sanofi Company69
已完成
2 期
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry DiseaseFabry DiseaseNCT02228460Genzyme, a Sanofi Company11
已完成
1 期
Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX Administered as Multiple Doses and Safety and Pharmacokinetics of BIRT 2584 XX Administered With and Without Food as Single Dose to Healthy Male VolunteersHealthyNCT02256761Boehringer Ingelheim74